One pill to stop malaria? new combo shows promise
NCT ID NCT05974267
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single dose of two antimalarial drugs, M5717 and pyronaridine, can clear the malaria parasite from the blood and prevent new infections in people who have the parasite but no symptoms. 192 adults and adolescents in malaria-endemic areas took part. The goal is to find a simple, effective way to prevent malaria with just one treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- M5717 and pyronaridine (antimalarial drugs)
- What this could lead to
- If successful, this could lead to a simple, single-dose preventive treatment for malaria, reducing the need for multiple doses.
- What could go wrong
- This is an early Phase 2 trial with only 192 participants, so results may not apply to everyone. The combination may not provide long-lasting protection or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
192 people
The number who actually took part.
- Started
-
Nov 2023
- Finished
-
Dec 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants with Asymptomatic Plasmodium falciparum Malaria with no Fever or other sign of Acute Uncomplicated Malaria and, with Microscopic confirmation using Giemsa-stained thick film, and a Parasitemia of \>= 40 to \<= 10,000 Asexual Parasites/Microliter (μL) of Blood. * Axillary Temperature \< 37.0 degree Celcius (ºC) or oral/Tympanic/rectal Temperature\< 37.5ºC; without history of fever during the previous 48 hours. * Have a body weight \>= 45 kilogram (kg) * Participants capable of giving Signed Informed consent which includes Compliance with the requirements and restriction listed in the Informed consent form * Other Protocol defined Inclusion Criteria could apply Exclusion Criteria: * Participants with any disease requiring Chronic Treatment * Participants with any Preplanned surgery during the study * Participants with any previous Treatment with pyronaridine as part of a combination therapy during the last 3 months * Participants with any adequate Hematological, Hepatic, and renal function as defined in the Protocol * Other protocol defined Exclusion Criteria could apply
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malaria infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Groupe de Recherche Action en Sante (GRAS)
Ouagadougou, Burkina Faso
-
Kisumu County Referral Hospital
Kisumu, Kenya
-
MRC Unit The Gambia at LSHTM
Banjul, The Gambia
-
Ndola Teaching Hospital
Ndola, Zambia
More trials for these conditions
Other studies related to the condition(s) this trial covers.